The patients comprised seven women, median age 52 years (range 49-69), and three men aged 50, 59, and 67 years attending the thyroid clinic at this hospital. Thyrotoxicosis was confirmed biochemically and by an increased two-hour uptake of 1321. None of the patients were receiving antithyroid drugs, and all had diffuse thyroid enlargement. Doses of 131I ranged from 2 5 to 11 8 mCi (median 4 mCi). The diagnosis of transient hypothyroidism was based on a low serum thyroxine (T4) concentration. Serum T4, triiodothyronine (T3), and thyroid-stimulating hormone (TSH) concentrations were measured by radioimmunoassay. Normal ranges were: serum T4 60-140 nmol 1 (4 7-10 9 yg 100 ml), serum T3 1 2-2 7 nmol l (0 8-1 8 ng ml), and serum TSH < 6 mU 1. Statistical ng/100 ml. T3: I nmol 1 _ 0.65 ng ml.
(3 2 ngj'ml) (range 3 1-7 6 nmol/l; 2 0-4 9 ng/ml) to a median of 1 3 nmol/I (0 8 ng'ml) (range 1 0-1 9 nmol/l; 0 7-1 2 ng/ml) and recovered to a median of 1 95 nmol/l (1-3 ng,'ml) (range 1 2-2-5 nmol/l; 0 8-1-6 ng/ml 
Comment
In seven of our patients low serum T4 concentrations were found within three months of '31I treatment and had recovered by seven months. These changes were closely similar to those following subtotal thyroidectomy2 and were probably due to the same mechanisms-that is, a fluctuating titre of thyroid-stimulating immunoglobulins and delayed recovery of suppressed pituitary thyrotrophs. None of our patients became clinically hypothyroid during the transient depression of thyroid hormones, which is consistent with the findings that biochemical hypothyroidism during carbimazole treatment can precede clinical hypothyroidism by many weeks.5 Thus not all patients developing biochemical hypothyroidism soon after 1311 treatment need to start lifelong thyroxine replacement therapy. Also, two of our patients now have mildly raised thyroid hormone concentrations, and thyroxine treatment in these patients may be harmful.
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